Enlivex Therapeutics (ENLV)
(Real Time Quote from BATS)
$1.45 USD
-0.05 (-3.33%)
Updated Sep 20, 2024 03:54 PM ET
After-Market: $1.45 0.00 (0.00%) 4:12 PM ET
2-Buy of 5 2
F Value B Growth A Momentum B VGM
Cash flow Statements
Fiscal Year End for Enlivex Therapeutics Ltd falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -29.07 | -31.06 | -14.47 | -11.82 | -9.38 |
Depreciation/Amortization & Depletion | 0.84 | 0.78 | 0.55 | 0.29 | 0.21 |
Net Change from Assets/Liabilities | -1.82 | 0.80 | -1.36 | -0.31 | 1.04 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 6.53 | 5.53 | -2.26 | 0.84 | 1.10 |
Net Cash From Operating Activities | -23.52 | -23.95 | -17.54 | -11.01 | -7.04 |
Property & Equipment | -0.10 | -8.12 | -1.63 | -1.02 | -0.19 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -25.87 | 70.65 | -36.78 | -19.96 | -7.71 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 1.54 |
Net Cash from Investing Activities | -25.97 | 62.52 | -38.41 | -20.98 | -6.36 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.36 | 0.15 | 60.98 | 33.08 | 8.31 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 0.36 | 0.15 | 60.98 | 33.08 | 8.31 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | -0.41 | 0.39 | 0.83 |
Net Change In Cash & Equivalents | -49.13 | 38.72 | 4.62 | 1.49 | -4.27 |
Cash at Beginning of Period | 50.36 | 11.64 | 7.01 | 5.52 | 9.79 |
Cash at End of Period | 1.23 | 50.36 | 11.64 | 7.01 | 5.52 |
Diluted Net EPS | -1.56 | -1.69 | -0.81 | -0.90 | -1.11 |
Fiscal Year End for Enlivex Therapeutics Ltd falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -7.24 | -4.14 | -29.07 | -19.97 | -14.01 |
Depreciation/Amortization & Depletion | 0.35 | 0.19 | 0.84 | 0.64 | 0.42 |
Net Change from Assets/Liabilities | -0.39 | -0.96 | -1.82 | -2.84 | -2.42 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 0.97 | 0.40 | 6.53 | 3.93 | 3.20 |
Net Cash From Operating Activities | -6.31 | -4.51 | -23.52 | -18.25 | -12.81 |
Property & Equipment | 0.11 | 0.13 | -0.10 | -0.15 | -0.12 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 4.14 | 4.92 | -25.87 | -29.96 | -33.93 |
Other Investing Activities | 0.05 | 0.05 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 4.30 | 5.10 | -25.97 | -30.10 | -34.05 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 4.94 | 0.52 | 0.36 | 0.36 | 0.36 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 4.94 | 0.52 | 0.36 | 0.36 | 0.36 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 2.94 | 1.11 | -49.13 | -47.99 | -46.50 |
Cash at Beginning of Period | 1.23 | 1.23 | 50.36 | 50.36 | 50.36 |
Cash at End of Period | 4.17 | 2.34 | 1.23 | 2.37 | 3.86 |
Diluted Net EPS | -0.16 | -0.22 | -0.48 | -0.32 | -0.37 |